评估抗AR142（一种源自丙型肝炎病毒核心序列的合成肽）抗体在非甲非乙型慢性肝病诊断中的作用。
Evaluation of antibody against AR142, a synthetic peptide derived from the core sequence of hepatitis C virus, in the diagnosis of non-A, non-B chronic liver disease.
作者信息
Du L, Shimomura H, Nakagawa H, Hasui T, Tsuji H, Wato M, Kondo J, Ukida M, Yamada G, Tsuji T
机构信息
First Department of Internal Medicine, Okayama University Medical School.
出版信息
Intern Med. 1993 Nov;32(11):843-8. doi: 10.2169/internalmedicine.32.843.
We evaluated serum anti-hepatitis C virus (HCV) using a synthetic peptide (AR142) which includes an epitope in the core region of HCV. The incidence of anti-AR142 in 98 patients with type non-A, non-B chronic liver diseases (NANB-CLD) was 89.8%, while all the 28 patients with non-type C chronic liver diseases were negative for anti-AR142. Among 98 NANB-CLD patients, 74 were positive for both anti-AR142 and anti-C100-3, 23 showed discordant results, and one was positive for neither. Eighty-one NANB-CLD patients underwent reverse transcription-polymerase chain reaction assay to detect viremia and 76 (93.8%) had a detectable level of HCV-RNA. Titers of anti-AR142 were not different among groups of different disease activities, genotypes of HCV, nor amount of serum HCV-RNA. These observations suggest that anti-AR142 could be a useful marker for chronic HCV infection.
我们使用一种合成肽（AR142）评估血清抗丙型肝炎病毒（HCV），该合成肽包含HCV核心区域的一个表位。98例非甲非乙型慢性肝病（NANB-CLD）患者中抗AR142的发生率为89.8%，而28例非丙型慢性肝病患者抗AR142均为阴性。在98例NANB-CLD患者中，74例抗AR142和抗C100-3均为阳性，23例结果不一致，1例两者均为阴性。81例NANB-CLD患者接受逆转录-聚合酶链反应检测以检测病毒血症，76例（93.8%）可检测到HCV-RNA水平。不同疾病活动度组、HCV基因型组或血清HCV-RNA量组之间抗AR142滴度无差异。这些观察结果表明抗AR142可能是慢性HCV感染的一个有用标志物。
Zotero 插件